International Journal on Science and Technology

E-ISSN: 2229-7677   •   Impact Factor: 9.88

A Widely Indexed Open Access Peer Reviewed Multidisciplinary Bi-monthly Scholarly International Journal

Call for Paper Volume 16 Issue 2 April-June 2025 Submit your research before last 3 days of June to publish your research paper in the issue of April-June.
Submit Research Paper Join as a Reviewer

Plagiarism is checked by the leading plagiarism checker TurnItIn

Call for Paper

Volume 16 Issue 2
April-June 2025

Submit your research paper

Indexing Partners
Academia Advanced Sciences Index Bielefeld Academic Search Engine CiteSeer DRJI Google Scholar Independent Search Engine & Directory Network ISI (International Scientific Indexing) Issuu Mendeley Research Networks
RefSeek ResearcherId - Thomson Reuters ResearchGate Scirus Scribd Semantic Scholar UTeM - Universiti Teknikal Malaysia Melaka Wiki for Call for Papers WorldCat Zenodo

Hesperetin as a Potential Drug Candidate for the Treatment of Pancreatic Cancer

Author(s) Sakshi Shahapurmath, Bhuvaneshwari R. Sharannavar
Country India
Abstract Pancreatic cancer remains one of the most lethal malignancies worldwide, characterized by late diagnosis, rapid progression, and poor responsiveness to existing therapeutic modalities. The search for novel, safe, and effective anticancer agents has drawn considerable attention to bioactive natural compounds, particularly flavonoids. Hesperetin, a flavanone derived from citrus fruits, has demonstrated promising anticancer properties in various in vitro and in vivo studies. This mini-review highlights the pharmacological potential of hesperetin against pancreatic cancer, focusing on its physicochemical and pharmacokinetic profiles, biological activities, and underlying mechanisms of action. Hesperetin exerts anti-proliferative, pro-apoptotic, anti-angiogenic, and anti-metastatic effects through modulation of key oncogenic pathways, including PI3K/Akt/mTOR and NF-κB signaling. However, its clinical applicability is limited by poor water solubility, low bioavailability, and rapid metabolic degradation. Advanced nanocarrier-based formulations have been proposed to overcome these limitations and enhance therapeutic efficacy. This review also discusses current challenges and outlines future research directions necessary for the clinical development of hesperetin as a potential therapeutic or adjuvant agent in pancreatic cancer treatment.
Keywords Hesperetin, Pancreatic cancer, Flavonoids, Anticancer activity, Nanoparticle drug delivery, Natural compounds
Field Medical / Pharmacy
Published In Volume 16, Issue 2, April-June 2025
Published On 2025-06-05
DOI https://doi.org/10.71097/IJSAT.v16.i2.5340
Short DOI https://doi.org/g9pz73
View / Download PDF File

Share this


CrossRef

CrossRef DOI is assigned to each research paper published in our journal.

IJSAT DOI prefix is
10.71097/IJSAT

Downloads
Research Paper Format Copyright Permission Form and Undertaking Form Cover Page Vol 15 Isu 4Cover Page Vol 15 Isu 3Cover Page Vol 15 Isu 2

All research papers published on this website are licensed under Creative Commons Attribution-ShareAlike 4.0 International License, and all rights belong to their respective authors/researchers.

CC-BY-SA Open Access

About IJSAT
Fees & Payment
Current Issue
Publication Archive 		Submit Research Paper
Track Submission Status
Publication Guidelines
Publication Ethics
Peer Review & Plagiarism 		Join as a Reviewer
Editors & Reviewers
Reviewer Referral Program
Get Reviewer Membership Certi. 		Website/Journal Policies
Usage Policy
Content Policies
Privacy Policy
Contact Us Message on WhatsApp +91-9687-182-185 editor@ijsat.org